Additional file 1 of A comprehensive comparison of the safety and efficacy of drugs in the treatment of idiopathic pulmonary fibrosis: a network meta-analysis based on randomized controlled trials

Additional file 1: Figure S1. The forest plot of consistency test of SAEs. Figure S2. Forest plot of pairwise comparison of the incidence of SAEs.  (PLA: Placebo; NIN:Nintedanib; PIR: Pirfenidone; SIL: Sildenafil; AMB: Ambrisentan; PAM: Pamrevlumab; BOS: Bosentan; MAC: Macitentan; IMA: Imatinib; GLPG:GLPG1690; SIM: Simtuzumab; WAR: Warfarin; PRM: PRM151;NAC:N-acetylcysteine.). Figure S3. SUCRA ranking chart of the incidence of SAEs. Figure S4. The forest plot of consistency test of all-cause mortality. Figure S5. Forest plot of pairwise comparison of all-cause mortality, (PLA: Placebo; NIN: Nintedanib; PIR:Pirfenidone; SIL: Sildenafil; AMB: Ambrisentan; PAM: Pamrevlumab; BOS: Bosentan; MAC:Macitentan; IMA: Imatinib; SIM: Simtuzumab; WAR: Warfarin; NAC:N-acetylcysteine.). Figure S6. SUCRA ranking chart of all-cause mortality. Figure S7. The forest plot of consistency test of FVC (L) absolute change from baseline. Figure S8. Forest plot of pairwise comparison of FVC (L) absolute change from baseline. (PLA: Placebo; NIN: Nintedanib; PAM: Pamrevlumab; BOS: Bosentan; MAC: Macitentan; IMA:Imatinib; GLPG:GLPG1690;WAR:Warfarin; PRM: PRM151;NAC:N-acetylcysteine.). Figure S9. SUCRA ranking chart of FVC (L) absolute change from baseline. Figure S10. The forest plot of consistency test of FVC (% predicted)absolute change from baseline. Figure S11. Forest plot of pairwise comparison of FVC (% predicted) absolute change from baseline. (PLA: Placebo; NIN: Nintedanib; PIR: Pirfenidone; SIL: Sildenafil; AMB: Ambrisentan; PAM: Pamrevlumab; WAR:Warfarin; PRM: PRM151.). Figure S12. SUCRA ranking chart of FVC (% predicted) absolute change from baseline. Figure S13. The forest plot of consistency test of the proportion of patients with decline in FVC≥10% predicted. Figure S14. Forest plot of pairwise comparison of the proportion of patients with decline in FVC≥10% predicted.  (PLA:Placebo; NIN: Nintedanib; PIR: Pirfenidone; AMB: Ambrisentan; PAM: Pamrevlumab; WAR:Warfarin.). Figure S15. SUCRA ranking chart of the proportion of patients with decline in FVC≥10% predicted. Figure S16. The funnel chart of bias generation detected by Begg rank correlation. Figure S17. The funnel chart generated by Egger's test. Figure S18. Influence analysis results of the five main outcomes. Table S1. The search strategy of PubMed. Table S2. Quality evaluation of the 24 included studies. Table S3. Influence analysis results data of the incidence of SAEs. Table S4. Influence analysis results data of all-cause mortality. Table S5. Influence analysis results data of FVC (L) absolute change from baseline. Table S6. Influence analysis results data of FVC (% predicted)absolute change from baseline. Table S7. Influence analysis results data of the proportion of patients with decline in FVC≥10% predicted.